Bristol-Myers Squibb Company v. Unichem Laboratories, Ltd.
1:17-cv-00382
Overview
Parties
Defendant
Unichem Laboratories, Ltd. Operating Company
Represented By
6 Attorneys ListedPhillips, McLaughlin & Hall, P.A.
Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St
Phillips, Goldman, McLaughlin & Hall, P.A.
Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street
Plaintiff
Pfizer Inc. Operating Company
Represented By
3 Attorneys ListedFarnan LLP
919 North Market Street, 12th Floor
Farnan LLP
919 North Market Street, 12th Floor
Bristol-Myers Squibb Company NPE (Individual / Inventor)
Represented By
10 Attorneys ListedFarnan LLP
919 North Market Street, 12th Floor
Farnan LLP
919 North Market Street, 12th Floor
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 4 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🌐 PCT International (WIPO) | PCT World Application | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → |
Bristol-Myers Squibb Company v. Biocon Pharma Limited
Bristol-Myers Squibb Company v. ScieGen Pharmaceuticals, Inc.
Coding Technologies, LLC v. Calix, Inc.
Bristol-Myers Squibb Company v. Prinston Pharmaceutical Inc.
Bristol-Myers Squibb Company v. Mylan Pharmaceuticals Inc.
Bristol-Myers Squibb Company v. Bionpharma Inc.
Bristol-Myers Squibb Company v. Sigmapharm Laboratories, LLC
Bristol-Myers Squibb Company v. Impax Laboratories LLC
Bristol-Myers Squibb Company v. Wockhardt Bio AG
Bristol-Myers Squibb Company v. Dr. Reddys Laboratories, Ltd.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US9326945
Apixaban formulations
|
Filed: 2011-02-24
Issued: 2016-05-03
|
Active (4.3 yrs remaining)
Expires: 2031-02-24
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term — No obviousness-type double patenting noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
1
Dispositive
0
Granted
0
Denied
0
Pending / Review
1
Motions by Category
Key Dispositive Motions & Rulings